Fitch maintains Bristol-Myers Squibb's (BMY) debt rating at A+ and its outlook at Negative...

|About: Bristol-Myers Squibb Company (BMY)|By:, SA News Editor

Fitch maintains Bristol-Myers Squibb's (BMY) debt rating at A+ and its outlook at Negative following the drug company's deal to buy Inhibitex (INHX) for $2.5B. While Bristol has enough cash to pay for Inhibitex, the latter won't provide immediate relief to an expected fall in Bristol's revenues because of the expiration of patents.